External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ISTH 2024

June 22 - June 26

Bangkok, Thailand

isth.org

Add to calendar

Medical Materials

Agenda

Coming soon

06:45 AM

Duration 15mins Ballroom B2

Long-term follow-up of participants in the Phase I/II trial of dirloctocogene samoparvovec (SPK-8011): durable FVIII expression and clinically meaningful reduction of bleeding

George L, Croteau SE, Chang T, Eyster ME, Tran H, Ragni MV, Sullivan S, Rasko JEJ, Moormeier J, Angchaisuksiri P, Teitel J, Kenet G, Wynn T, Samelson-Jones B, Jaeger S, Ramos J, Mingozzi F, Levy G

Haematology | Hemophilia A

Add to calendar

06:45 AM

Duration 60mins Bangkok, Thailand

Long-term effectiveness and safety of emicizumab in people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Poon MC, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Polito L, Moreno K, Santos M, Iserman E, Matino D, Iorio A

Haematology | Hemophilia A

Add to calendar

Duration 60mins Bangkok, Thailand

Relationship between current and historic clinical characteristics and bleeding outcomes in people with severe haemophilia A on emicizumab without recent FVIII inhibitors: a multivariate analysis of data from the CHESS studies

Polito L, Oellerich M, Chafaie R, Burke T, Blenkiron T, Ferri Grazzi E

Haematology | Hemophilia A

Add to calendar

Duration 60mins Bangkok, Thailand

Hemoglobin improvement among patients with hemophilia A treated with emicizumab prophylaxis: post hoc analysis of the HAVEN 1, 3, 4 and STASEY trials

Batsuli G, Gupta S, Tzeng E, Gao L, Lim E, Sidonio Jr R

Haematology | Hemophilia A

Add to calendar

Duration 60mins Bangkok, Thailand

Long-term safety and effectiveness of emicizumab in people with hemophilia A in the Hemophilia Natural History Study (ATHN 7)

Recht M, Carpenter SL, Lee L, Mclean TW, Morton P, Staber JM, Wang M, Chrisentery-Singleton T

Haematology | Hemophilia A

Add to calendar

Duration 60mins Bangkok, Thailand

Emicizumab and females with hemophilia A in the ATHNdataset and prospective ATHN 7 study

Chrisentery-Singleton T, Lee L, Morton P, Recht M

Haematology | Hemophilia A

Add to calendar

Duration 60mins Bangkok, Thailand

NXT007, a novel bispecific antibody, in factor VIII chromogenic substrate assays

Kiialainen A, Bektic L, Schmitt C, Hart D, David T, Chen D, Locke M

Haematology | Hemophilia A

Add to calendar

Duration 60mins Bangkok, Thailand

Non-interventional study on health-related quality of life, physical activity and bleeds in severe non-inhibitor hemophilia A patients with a bleeding phenotype on FVIII prophylaxis in the Nordics

Ranta S, Lassila R, Westesson LM, Quere S, Hoffmann M, Castro Sanchez AY, Czirok T, Holme PA, Astermark J

Haematology | Hemophilia A

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.